Renate & Hans Schleussner Award

Renate & Hans Schleussner Award

Third Renate & Hans Schleussner Research Award 2023/2024 on Hyper-Immunoglobulins now online.

Careers

Careers

Passionate to help us save lives?

War in Ukraine

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
CMV Hyperimmunglobulin ((CMVIG) ) - Prevention of prenatal CMV transmission
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia
Trimodulin (BT588) - "Severe" COVID-19
Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Pipeline

Press releases

Biotest successfully meets primary endpoint in phase II...

14.02.2024,

14.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

30.01.2024,

30.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Preliminary announcement of the publication of financia...

22.01.2024,

22.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest AG opens 11th plasma collection centre in Germa...

18.01.2024,

18.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

11.01.2024,

11.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest expands its clinical development program for tr...

12.12.2023,

12.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest’s Trimodulin shows reduced mortality in patient...

28.11.2023,

28.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases EBIT to Euro 125.4 million in the fir...

02.11.2023,

02.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Peter Janssen appointed new Chairman of the Board of Bi...

05.10.2023,

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Peter Janssen appointed new Chairman of the Board of Biotest AG Dreieich, 5 October 2023. In its m ... [More]

Increase of the EBIT guidance

05.10.2023,

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Increase of the EBIT guidance Dreieich, 05 October 2023. Against the background of the agreements ... [More]

Biotest receives approval for innovative immunoglobulin...

21.09.2023,

21.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest treats first patient with severe community-acqu...

12.09.2023,

12.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

US Food and Drug Administration FDA accepts marketing a...

07.09.2023,

07.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest treats first shingles patient with Varitect® CP...

05.09.2023,

05.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest Supervisory Board extends Management Board cont...

04.09.2023,

04.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases EBIT to Euro 19.8 million in the firs...

10.08.2023,

10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases EBIT to Euro 19.8 million

27.07.2023,

27.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest presents gigantic artwork to visualize its sust...

01.06.2023,

01.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Annual General Meeting of Biotest AG elects Raimon Grif...

09.05.2023,

09.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest’s Hyperimmunoglobulin Cytotect® CP receives fiv...

04.05.2023,

04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.